Correction to: DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation (Journal of Experimental and Clinical Cancer Research (2019) 38 (474) DOI: 10.1186/s13046-019-1442-2)

Ssu Chuan Lai, Yu Ting Su, Ching Chi Chi, Yung Che Kuo, Kam Fai Lee, Yu Chih Wu, Pei Chi Lan, Muh Hwa Yang, Te Sheng Chang*, Yen Hua Huang

*此作品的通信作者

研究成果: Comment/debate

2 引文 斯高帕斯(Scopus)

摘要

In the original publication of this article [1], labelling within Fig. 7a was incorrect. The updated figure is shown below, with 'DMT1' now corrected to read 'DNMT1'(Figure Presented). The authors sincerely apologize for the inconvenience caused to the readers.

原文English
文章編號10
期刊Journal of Experimental and Clinical Cancer Research
39
發行號1
DOIs
出版狀態Published - 13 1月 2020

指紋

深入研究「Correction to: DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation (Journal of Experimental and Clinical Cancer Research (2019) 38 (474) DOI: 10.1186/s13046-019-1442-2)」主題。共同形成了獨特的指紋。

引用此